8-K - Abbott Laboratories | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Abbott Laboratories completed the public offering and issuance of $20,000,000,000 on March 9, 2026. This constitutes entry into a material definitive agreement and creation of a direct financial obligation, as disclosed under Items 1.01 and 2.03.

Key Takeaways

1Abbott Laboratories completed public offering and issuance of $20,000,000,000 on March 9, 2026

2Item 1.01: Entry into a Material Definitive Agreement

3Item 2.03: Creation of a Direct Financial Obligation

4Exhibit 4.1: Indenture dated March 10, 2015 between Abbott Laboratories and U.S. Bank National Association

Current Report Details

Event Type

Material Agreement

Financing

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggr

Material Agreement

$1.00B$2.25B$2.50B$2.75B

2.03

. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information included in Item 1.01 of thi

Financing

9.01

. Financial Statements and Exhibits. Exhibit No. Description 4.1 Indenture, dated as of March 10, 2015, between Abbott Laboratories and U.S. Bank National Assoc

Exhibits Only

Transaction Details

Material Agreement

Parties: Abbott Laboratories, U.S. Bank National Association

•Indenture dated as of March 10, 2015

Debt / Financing

Instrument: Public Offering
Principal: 20000000000

Exhibits (3)

4.2

EXHIBIT 4.2

5.1

EXHIBIT 5.1

8-K

FORM 8-K